Pfizer is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and distributing innovative medicines and vaccines across various therapeutic areas including oncology, cardiovascular health, and infectious diseases. Operating within the Drug Manufacturers - General industry, Pfizer's business model relies on a diverse portfolio of established brands and a robust pipeline, often enhanced through strategic collaborations and acquisitions, to address unmet medical needs worldwide. The company's recent performance shows a mixed trend in earnings per share (EPS) and revenue. In Q4 2024, Pfizer reported an actual EPS of $0.63 against an estimate of $0.45918, and revenue of $17.76 billion. This was followed by Q1 2025, where actual EPS was $0.92, significantly exceeding the estimate of $0.67406, with revenue at $13.71 billion. However, Q2 2025 saw actual EPS of $0.78 against an estimate of $0.5738, and Q3 2025 reported actual EPS of $0.87 versus an estimate of $0.63307. The most recent reported quarter, Q4 2025, showed actual EPS of $0.66 against an estimate of $0.5775, with revenue at $17.56 billion, indicating a pattern of beating EPS estimates in the last four reported quarters, though revenue figures were not consistently provided against estimates. Looking at the year-over-year growth trajectory, Pfizer's historical performance indicates a strong ability to meet or exceed analyst expectations for earnings, particularly in recent quarters. The company has demonstrated a consistent pattern of EPS beats, suggesting operational efficiency and successful product performance. While specific year-over-year revenue growth figures are not fully detailed across all periods, the reported revenue in Q4 2025 was $17.557 billion, slightly above the estimate of $17.119 billion, continuing a trend of meeting revenue expectations when provided. Recent news highlights Pfizer's strategic exploration of drug development collaborations with Chinese biotech firms and its involvement in the GLP-1 market through a manufacturing partnership with Amneal Pharmaceuticals, leveraging its Metsera acquisition. The company's robust Phase 3 pipeline is seen as a key factor supporting potential momentum and dividend safety, despite post-COVID revenue and earnings declines. Investors will be watching for the impact of these new collaborations and the performance of its oncology segment, particularly drivers like Xtandi and Lorbrena, as well as the sustainability of its dividend yield, in upcoming quarters. Key will be the company's ability to translate its R&D investments and strategic partnerships into consistent revenue growth and earnings beats, especially as it navigates patent expirations and evolving market dynamics.
